C4 Therapeutics Analyst Ratings
C4 Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/06/2023 | -38.65% | Morgan Stanley | $3 → $1 | Upgrades | Underweight → Equal-Weight |
11/03/2023 | 881.6% | BMO Capital | $18 → $16 | Maintains | Outperform |
11/02/2023 | 329.45% | HC Wainwright & Co. | $17 → $7 | Maintains | Buy |
10/09/2023 | 22.7% | B of A Securities | $5 → $2 | Maintains | Neutral |
08/09/2023 | 942.94% | HC Wainwright & Co. | $25 → $17 | Maintains | Buy |
05/30/2023 | 513.5% | Evercore ISI Group | $20 → $10 | Maintains | Outperform |
05/12/2023 | 84.05% | Morgan Stanley | $5 → $3 | Maintains | Underweight |
05/08/2023 | 1433.74% | HC Wainwright & Co. | $35 → $25 | Maintains | Buy |
03/28/2023 | 206.75% | B of A Securities | $11 → $5 | Maintains | Neutral |
02/27/2023 | 206.75% | Morgan Stanley | $6 → $5 | Maintains | Underweight |
02/24/2023 | 2047.24% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
02/24/2023 | 206.75% | JP Morgan | $15 → $5 | Downgrades | Neutral → Underweight |
01/03/2023 | 452.15% | Wells Fargo | $11 → $9 | Maintains | Equal-Weight |
11/08/2022 | 574.85% | Wells Fargo | $12 → $11 | Maintains | Equal-Weight |
11/04/2022 | 820.25% | JP Morgan | $22 → $15 | Downgrades | Overweight → Neutral |
10/11/2022 | 268.1% | Morgan Stanley | → $6 | Initiates Coverage On | → Underweight |
05/09/2022 | 2047.24% | HC Wainwright & Co. | $63 → $35 | Maintains | Buy |
04/28/2022 | 513.5% | Credit Suisse | → $10 | Initiates Coverage On | → Underperform |
04/18/2022 | 1495.09% | UBS | $64 → $26 | Maintains | Buy |
04/11/2022 | 1126.99% | BMO Capital | $57 → $20 | Maintains | Outperform |
03/10/2022 | 2538.04% | JP Morgan | → $43 | Initiates Coverage On | → Overweight |
02/10/2022 | 1433.74% | Wells Fargo | → $25 | Initiates Coverage On | → Equal-Weight |
11/23/2021 | 3212.88% | B of A Securities | → $54 | Initiates Coverage On | → Buy |
10/14/2021 | 4010.43% | SVB Leerink | → $67 | Initiates Coverage On | → Outperform |
09/30/2021 | 2660.74% | Stifel | → $45 | Initiates Coverage On | → Hold |
06/24/2021 | 3212.88% | Brookline Capital | → $54 | Initiates Coverage On | → Buy |
06/04/2021 | 3765.03% | HC Wainwright & Co. | → $63 | Initiates Coverage On | → Buy |
03/31/2021 | 3274.23% | BMO Capital | → $55 | Initiates Coverage On | → Outperform |
10/27/2020 | 1924.54% | BMO Capital | → $33 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/06/2023 | -38.65% | 摩根士丹利 | 3 美元 → 1 美元 | 升级 | 体重不足 → 重量相等 |
11/03/2023 | 881.6% | BMO Capital | 18 美元 → 16 美元 | 维护 | 跑赢大盘 |
11/02/2023 | 329.45% | HC Wainwright & Co. | 17 美元 → 7 美元 | 维护 | 买 |
2023 年 9 月 10 日 | 22.7% | B of A 类证券 | 5 美元 → 2 美元 | 维护 | 中立 |
08/09/2023 | 942.94% | HC Wainwright & Co. | 25 美元 → 17 美元 | 维护 | 买 |
05/30/2023 | 513.5% | Evercore ISI 集团 | 20 美元 → 10 美元 | 维护 | 跑赢大盘 |
05/12/2023 | 84.05% | 摩根士丹利 | 5 美元 → 3 美元 | 维护 | 体重不足 |
05/08/2023 | 1433.74% | HC Wainwright & Co. | 35 美元 → 25 美元 | 维护 | 买 |
03/28/2023 | 206.75% | B of A 类证券 | 11 美元 → 5 美元 | 维护 | 中立 |
02/27/2023 | 206.75% | 摩根士丹利 | 6 美元 → 5 美元 | 维护 | 体重不足 |
02/24/2023 | 2047.24% | HC Wainwright & Co. | → 35 美元 | 重申 | → 购买 |
02/24/2023 | 206.75% | 摩根大通 | 15 美元 → 5 美元 | 降级 | 中性 → 体重不足 |
01/03/2023 | 452.15% | 富国银行 | 11 美元 → 9 美元 | 维护 | 重量相等 |
2022 年 8 月 11 日 | 574.85% | 富国银行 | 12 美元 → 11 美元 | 维护 | 重量相等 |
2022 年 4 月 11 日 | 820.25% | 摩根大通 | 22 美元 → 15 美元 | 降级 | 超重 → 中性 |
2022 年 10 月 11 日 | 268.1% | 摩根士丹利 | → 6 美元 | 启动覆盖范围开启 | → 体重不足 |
05/09/2022 | 2047.24% | HC Wainwright & Co. | 63 美元 → 35 美元 | 维护 | 买 |
04/28/2022 | 513.5% | 瑞士信贷 | → 10 美元 | 启动覆盖范围开启 | → 表现不佳 |
04/18/2022 | 1495.09% | 瑞银(UBS) | 64 美元 → 26 美元 | 维护 | 买 |
2022 年 11 月 4 日 | 1126.99% | BMO Capital | 57 美元 → 20 美元 | 维护 | 跑赢大盘 |
03/10/2022 | 2538.04% | 摩根大通 | → 43 美元 | 启动覆盖范围开启 | → 超重 |
02/10/2022 | 1433.74% | 富国银行 | → 25 美元 | 启动覆盖范围开启 | → 重量相等 |
11/23/2021 | 3212.88% | B of A 类证券 | → 54 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 10 月 14 日 | 4010.43% | SVB Leerink | → 67 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
09/30/2021 | 2660.74% | Stifel | → 45 美元 | 启动覆盖范围开启 | → 按住 |
2021 年 6 月 24 日 | 3212.88% | 布鲁克林资本 | → 54 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 4 月 6 日 | 3765.03% | HC Wainwright & Co. | → 63 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 3 月 31 日 | 3274.23% | BMO Capital | → 55 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
10/27/2020 | 1924.54% | BMO Capital | → 33 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for C4 Therapeutics (CCCC)?
C4 Therapeutics(CCCC)的目标价格是多少?
The latest price target for C4 Therapeutics (NASDAQ: CCCC) was reported by Morgan Stanley on November 6, 2023. The analyst firm set a price target for $1.00 expecting CCCC to fall to within 12 months (a possible -38.65% downside). 14 analyst firms have reported ratings in the last year.
摩根士丹利于2023年11月6日公布了C4 Therapeutics(纳斯达克股票代码:CCCC)的最新目标股价。该分析公司将目标股价定为1.00美元,预计CCCC将在12个月内降至12个月内(可能下跌-38.65%)。去年有14家分析公司公布了评级。
What is the most recent analyst rating for C4 Therapeutics (CCCC)?
分析师对C4 Therapeutics(CCCC)的最新评级是多少?
The latest analyst rating for C4 Therapeutics (NASDAQ: CCCC) was provided by Morgan Stanley, and C4 Therapeutics upgraded their equal-weight rating.
摩根士丹利对C4 Therapeutics(纳斯达克股票代码:CCCC)的最新分析师评级由摩根士丹利提供,C4 Therapeutics上调了同等权重评级。
When is the next analyst rating going to be posted or updated for C4 Therapeutics (CCCC)?
C4 Therapeutics(CCCC)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of C4 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for C4 Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与C4 Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。C4 Therapeutics的最新评级是在2023年11月6日公布的,因此您应该预计下一个评级将在2024年11月6日左右公布。
Is the Analyst Rating C4 Therapeutics (CCCC) correct?
分析师对C4 Therapeutics(CCCC)的评级正确吗?
While ratings are subjective and will change, the latest C4 Therapeutics (CCCC) rating was a upgraded with a price target of $3.00 to $1.00. The current price C4 Therapeutics (CCCC) is trading at is $1.63, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的C4 Therapeutics(CCCC)评级已上调,目标股价为3.00美元至1.00美元。C4 Therapeutics(CCCC)目前的交易价格为1.63美元,超出了分析师的预期区间。